(ILM1) Medios - Ratings and Ratios
Cytostatic,Antibody,Parenteral,Oncology,Neurology
ILM1 EPS (Earnings per Share)
ILM1 Revenue
Description: ILM1 Medios October 27, 2025
Medios AG (XETRA: ILM1) is a Berlin-based specialty pharmaceutical distributor that serves the German market through three operating segments: Patient-Specific Therapies (compounding cytostatic drugs, antibody therapies, and parenteral nutrition for pharmacies), International Business (procurement of APIs, sterile/non-sterile drug manufacturing, and home-care distribution to public and hospital pharmacies abroad), and Pharmaceutical Supply (offering oncology, neurology, auto-immunity, ophthalmology, infectiology, and hemophilia products). The firm’s core model is contract manufacturing and wholesale distribution, with a strong emphasis on high-margin, patient-tailored therapies.
According to the latest FY 2023 filing, Medios reported revenue of roughly €1.2 billion, a YoY increase of 5 % driven primarily by growth in its International Business segment, which saw a 9 % rise in order intake from home-care contracts. EBITDA margin hovered around 6 %, reflecting the cost-intensive nature of sterile compounding but also the pricing power afforded by its niche product mix. Key economic drivers include Germany’s aging population-projected to increase demand for oncology and neurology drugs by ~3 % annually-and ongoing reforms to the Arzneimittelpreisverordnung (pharmaceutical price regulation), which could compress margins if reimbursement rates tighten. Sector-wide, the shift toward outpatient and home-care treatment is expanding the addressable market for specialty distributors, while tighter EU GMP compliance standards raise entry barriers for competitors.
For a deeper quantitative assessment of Medios’ valuation metrics, the ValueRay platform provides a transparent, data-driven model worth reviewing.
ILM1 Stock Overview
| Market Cap in USD | 359m |
| Sub-Industry | Health Care Distributors |
| IPO / Inception |
ILM1 Stock Ratings
| Growth Rating | -45.0% |
| Fundamental | 65.0% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -33.3% |
| Analyst Rating | - |
ILM1 Dividends
Currently no dividends paidILM1 Growth Ratios
| Growth Correlation 3m | -57.7% |
| Growth Correlation 12m | 20.4% |
| Growth Correlation 5y | -94% |
| CAGR 5y | -15.32% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.30 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.56 |
| Sharpe Ratio 12m | -0.11 |
| Alpha | -47.57 |
| Beta | 1.373 |
| Volatility | 36.61% |
| Current Volume | 22.5k |
| Average Volume 20d | 44.5k |
| Stop Loss | 11.8 (-3.8%) |
| Signal | -0.57 |
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income (18.8m TTM) > 0 and > 6% of Revenue (6% = 118.0m TTM) |
| FCFTA 0.06 (>2.0%) and ΔFCFTA -7.08pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 8.45% (prev -0.68%; Δ 9.12pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.07 (>3.0%) and CFO 63.0m > Net Income 18.8m (YES >=105%, WARN >=100%) |
| Net Debt (-87.8m) to EBITDA (81.4m) ratio: -1.08 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.92 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (25.5m) change vs 12m ago 4.39% (target <= -2.0% for YES) |
| Gross Margin 9.73% (prev 3.62%; Δ 6.11pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 212.7% (prev 197.2%; Δ 15.46pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 3.20 (EBITDA TTM 81.4m / Interest Expense TTM 13.5m) >= 6 (WARN >= 3) |
Altman Z'' 2.14
| (A) 0.18 = (Total Current Assets 346.3m - Total Current Liabilities 180.2m) / Total Assets 918.1m |
| (B) 0.10 = Retained Earnings (Balance) 91.1m / Total Assets 918.1m |
| (C) 0.05 = EBIT TTM 43.3m / Avg Total Assets 925.2m |
| (D) 0.30 = Book Value of Equity 116.6m / Total Liabilities 394.8m |
| Total Rating: 2.14 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 64.97
| 1. Piotroski 4.50pt = -0.50 |
| 2. FCF Yield 12.99% = 5.0 |
| 3. FCF Margin 2.82% = 0.71 |
| 4. Debt/Equity 0.39 = 2.42 |
| 5. Debt/Ebitda -1.08 = 2.50 |
| 6. ROIC - WACC (= -1.47)% = -1.83 |
| 7. RoE 3.66% = 0.30 |
| 8. Rev. Trend 85.44% = 6.41 |
| 9. EPS Trend -0.72% = -0.04 |
What is the price of ILM1 shares?
Over the past week, the price has changed by -1.61%, over one month by -16.03%, over three months by -4.22% and over the past year by -19.97%.
Is Medios a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ILM1 is around 9.75 EUR . This means that ILM1 is currently overvalued and has a potential downside of -20.47%.
Is ILM1 a buy, sell or hold?
What are the forecasts/targets for the ILM1 price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 22.8 | 85.6% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 10.7 | -12.5% |
ILM1 Fundamental Data Overview January 01, 1970
Market Cap EUR = 311.2m (311.2m EUR * 1.0 EUR.EUR)
P/E Trailing = 16.4865
P/E Forward = 7.874
P/S = 0.1582
P/B = 0.7009
Beta = 1.373
Revenue TTM = 1.97b EUR
EBIT TTM = 43.3m EUR
EBITDA TTM = 81.4m EUR
Long Term Debt = 175.0m EUR (from longTermDebt, last fiscal year)
Short Term Debt = 31.0m EUR (from shortTermDebt, last quarter)
Debt = 204.6m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = -87.8m EUR (from netDebt column, last quarter)
Enterprise Value = 427.9m EUR (311.2m + Debt 204.6m - CCE 87.8m)
Interest Coverage Ratio = 3.20 (Ebit TTM 43.3m / Interest Expense TTM 13.5m)
FCF Yield = 12.99% (FCF TTM 55.6m / Enterprise Value 427.9m)
FCF Margin = 2.82% (FCF TTM 55.6m / Revenue TTM 1.97b)
Net Margin = 0.96% (Net Income TTM 18.8m / Revenue TTM 1.97b)
Gross Margin = 9.73% ((Revenue TTM 1.97b - Cost of Revenue TTM 1.78b) / Revenue TTM)
Gross Margin QoQ = 10.06% (prev 9.87%)
Tobins Q-Ratio = 0.47 (Enterprise Value 427.9m / Total Assets 918.1m)
Interest Expense / Debt = 1.23% (Interest Expense 2.52m / Debt 204.6m)
Taxrate = 27.34% (2.37m / 8.67m)
NOPAT = 31.4m (EBIT 43.3m * (1 - 27.34%))
Current Ratio = 1.92 (Total Current Assets 346.3m / Total Current Liabilities 180.2m)
Debt / Equity = 0.39 (Debt 204.6m / totalStockholderEquity, last quarter 523.3m)
Debt / EBITDA = -1.08 (Net Debt -87.8m / EBITDA 81.4m)
Debt / FCF = -1.58 (Net Debt -87.8m / FCF TTM 55.6m)
Total Stockholder Equity = 514.4m (last 4 quarters mean from totalStockholderEquity)
RoA = 2.05% (Net Income 18.8m / Total Assets 918.1m)
RoE = 3.66% (Net Income TTM 18.8m / Total Stockholder Equity 514.4m)
RoCE = 6.27% (EBIT 43.3m / Capital Employed (Equity 514.4m + L.T.Debt 175.0m))
RoIC = 5.57% (NOPAT 31.4m / Invested Capital 564.7m)
WACC = 7.03% (E(311.2m)/V(515.8m) * Re(11.07%) + D(204.6m)/V(515.8m) * Rd(1.23%) * (1-Tc(0.27)))
Discount Rate = 11.07% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 81.65 | Cagr: 3.51%
[DCF Debug] Terminal Value 58.15% ; FCFE base≈82.3m ; Y1≈54.0m ; Y5≈24.7m
Fair Price DCF = 12.58 (DCF Value 320.9m / Shares Outstanding 25.5m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: -0.72 | EPS CAGR: 6.55% | SUE: 2.09 | # QB: 2
Revenue Correlation: 85.44 | Revenue CAGR: 7.16% | SUE: 0.09 | # QB: 0